iTolerance
Pre-clinicalWe are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
About
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
Funding History
1Total raised: $15M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile